Skip to main content

Table 2 Demographics, clinical characteristics, and outcomes of PNC assay in 69 patients with SLE (SLE cohort)

From: The assessment of serum-mediated phagocytosis of necrotic material by polymorphonuclear leukocytes to diagnose and predict the clinical features of systemic lupus erythematosus: an observational longitudinal study

Characteristics Data
Age, yr  
 Mean (SD) 41.4 (13.7)
 Median (range) 39.2 (18–76)
Female sex, n (%) 63 (91.3)
Disease duration, yr, median (range) 7.5 (0–41)
Follow-up duration, d, median (range) 778 (139–1792)
Corticosteroid treatment, n (%) 33 (47.8)
Prednisolone equivalent, average dose last 2 mo, median (range) 10 (1–60) mg/d
Antimalarial treatment 46 (66.7)
Hydroxychloroquine, average dose last 2 mo, median (range) 200 (46.6–400) mg/d
Immunomodulatory treatment, n (%) 37 (53.6)
ACR classification criteria n (%)  
 Malar rash 46 (67 %)
 Discoid rash 18 (26 %)
 Photosensitivity 42 (61 %)
 Oral ulcer 16 (23 %)
 Arthritis 55 (80 %)
 Serositis 35 (51 %)
 Glomerulonephritis 35 (51 %)
 Hematologic disorder 38 (55 %)
 Neurologic disorder 3 (4 %)
 Immunologic disorder 53 (77 %)
 ANA positivity 69 (100 %)
Outcome of PNC assay, % CD66+PI+ PMNs  
 Mean (SD) 7.3 (9.0)
 Median (range) 3.4 (0.8–49.9)
  1. ACR American College of Rheumatology, ANA anti-nuclear antibodies; SD standard deviation, CD66+PI+ PMNs double-stained polymorphonuclear cells, PI propidium iodide, PNC phagocytosis of necrotic cell material